conducted a nationwide cohort study to assess the risk of lymphoma in adult patients with IBD exposed to thiopurine monotherapy, anti-TNF (infliximab, adalimumab) monotherapy and combination therapy and discovered that thiopurine monotherapy, anti-TNF monotherapy and combination therapy were all associated with a significantly increased risk of lymphoma in IBD patients compared with unexposed patients. Here, TNF is linked to lymphoma.